Efficacy and mechanism of curcumin in prevention and treatment of diabetes, liver cirrhosis from nonalcoholic fatty liver disease (NAFLD), and osteoporosis in the patients with type 2 diabetes

Phase 3

Completed

• Conditions: obesity; fatty liver; osteoporosis; curcuminoids extracttype 2 diabetesinsulin resistanceobesityfatty liverosteoporosis; curcuminoids extract; type 2 diabetes; insulin resistance

• Registration Number: TCTR20140303003
• Lead Sponsor: Thailand Research Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-03-03
• Study Completion: 2014-04-18
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 296

Inclusion Criteria

type 2 diabetes patients

Exclusion Criteria

- type 1 diabetes
- renal failure with serum creatinine > 2.0 md/dL
- secondary cause of chronic hepatitis
- Liver failure with AST and ALT over than 2.5 times of upper limit
- heavy alcoholic drinking
- receiving anti-hyperglycemic drugs ( TZD, DDP-IV inhibitor, insulin, GLP-1 agonist) and antihyperlipid drugs (fenofibrate, gemfibrozile and ezetrol)
- receiving other herbal
- secondary cause of hyperglycemia
- history of inflammatory and infection diseases
- pregnancy women
- history of gall stone or cholecystectomy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluate in the HOMA-Beta, pulse wave velocity, TNF-alpha, PHQ-9 scores 1 year t-test, Mann-Whitney U Test

Secondary Outcome Measures

Name	Time	Method
fasting blood glucose, HbA1c, HOMA-IR, pro-inflammatory cytokines, cardiometabolic risks, anti-oxidant activities, oxidative stress, liver steatosis, liver stiffness, serotonin level, 1 year t-test, Mann-Whitney U Test